Vanda Gains Fanapt Rights from Novartis for the U.S. Region - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:30PM CST
Vanda Pharmaceuticals Inc. (VNDA) recently announced that it has reached a settlement agreement with Novartis AG (Novartis) related to Fanapt.
BIIB: 340.89 (+5.13), VNDA: 14.69 (+1.11), SHPG: 209.29 (+0.07), NVS: 93.91 (+0.66)
Stock Market News for December 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:10AM CST
Benchmarks mostly settled in the green on Tuesday banking on better-than-expected revision to third quarter GDP numbers
KMI: 42.01 (+0.10), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), MON: 120.97 (-1.70), AMGN: 160.67 (+3.15), XOM: 93.78 (-0.81), BA: 131.24 (+1.21), SLB: 87.06 (-0.26), CELG: 109.60 (+3.48), LYB: 81.31 (-0.89), REG: 64.30 (-0.04), DD: 74.79 (-0.40), CVX: 113.47 (-0.48), OXY: 82.24 (-0.66), PX: 131.74 (-0.35), DOW: 46.01 (+0.03)
Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 24, 8:48AM CST
Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) market?
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), IMGN: 5.90 (+0.13), ABBV: 66.21 (+1.86)
Why I Expect The Biotech Sell-Off To Continue Into 2015
Sammy Pollack - at Seeking Alpha - Wed Dec 24, 7:08AM CST
BIIB: 340.89 (+5.13), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), IBB: 299.80 (+5.12), AMGN: 160.67 (+3.15), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)
Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 4.69% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 3:44PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $328.68 to a high of $353.79. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $337.71 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 340.89 (+5.13)
Biogen Idec Falls 4.69% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Dec 23, 3:43PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $328.68 to a high of $353.79. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $337.71 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 340.89 (+5.13)
Biogen Idec reports January 28
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:21PM CST
BIIB: 340.89 (+5.13)
Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 28, 2015
Business Wire - Tue Dec 23, 3:01PM CST
Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2014 financial results on Wednesday, January 28, 2015, before the financial markets open.
BIIB: 340.89 (+5.13)
Fresh Milestones For Dow, S&P 500 But Biotechs Hit
at Investor's Business Daily - Tue Dec 23, 1:48PM CST
The Dow Jones industrial average and S&P 500 notched fresh all-time highs Tuesday, but the Nasdaq lagged as biotech stocks sold off hard. The Dow added 0.6%, with about one-third of its components up 1% or more. The S&P 500 rose 0.4% and the Nasdaq...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), CDW: 35.75 (+0.14), CELG: 109.60 (+3.48), NOAH: 20.44 (-1.00), BIDU: 230.98 (-2.18), CALM: 42.45 (-1.73), ABG: 77.12 (+0.43), FLT: 149.17 (-0.93), REGN: 400.12 (+6.07)
Biotech Stocks Are Falling: 3 Top Stocks to Buy
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 23, 12:41PM CST
Source: Celgene Corp. Biotechnology stocks have been one of the market's darlings over the past year. The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has roughly doubled the S&P 500's return over the past 5 weeks. Today though, the ETF is...
BIIB: 340.89 (+5.13), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), CELG: 109.60 (+3.48)
Toys, Department Stores Rock, But Biotechs Tumble
at Investor's Business Daily - Tue Dec 23, 11:06AM CST
The euphoria over third-quarter GDP growth of 5% evaporated Tuesday morning, leaving stocks trading mixed at midday, with the Nasdaq leading other indexes off their best levels. The Nasdaq was off 0.1% ,the S&P 500 rose 0.3% and the Dow Jones...
HAS: 55.25 (+0.03), BIIB: 340.89 (+5.13), PCYC: 121.84 (+1.15), M: 64.26 (+0.22), CELG: 109.60 (+3.48), DDS: 122.53 (+0.53), ESRX: 85.48 (-0.40), MAT: 30.22 (-0.16), GILD: 91.29 (+1.84), JCP: 6.50 (-0.24), ALXN: 181.96 (+3.09), ABBV: 66.21 (+1.86)
Indexes Turn Mixed On Data; Celgene Dives
at Investor's Business Daily - Tue Dec 23, 9:43AM CST
Stocks backed off early gains and were mixed early Tuesday as investors wrestled through a jumble of economic news. The Dow Jones industrial average rose 0.4% and the S&P 500 added 0.2% as both indexes reached new highs. The Nasdaq shed its early...
DDS: 122.53 (+0.53), BIIB: 340.89 (+5.13), JNJ: 104.59 (+0.31), ABG: 77.12 (+0.43), GILD: 91.29 (+1.84), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), CELG: 109.60 (+3.48)
Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 5:10PM CST
The CHMP gave a positive opinion on the approval of Orexigen's (OREX) weight loss drug, Mysimba.
BIIB: 340.89 (+5.13), OREX: 5.98 (+0.01), AMGN: 160.67 (+3.15)
Genomic Health (GHDX) Shines on Prospective Cancer Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:50PM CST
Genomic Health (GHDX) strongly believes that its Oncotype DX prostate cancer test will strengthen its advanced next generation sequencing (NGS) platform and accelerate the development of future tests.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), AFFX: 9.80 (+0.05), GHDX: 32.44 (+1.32)
Roche to Acquire Austrian Biotechnology Company Dutalys - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:55PM CST
Roche (RHHBY) recently announced it has agreed to acquire a privately-held Austrian biotechnology company named Dutalys GmbH.
AGN: 210.12 (+0.95), BIIB: 340.89 (+5.13), ABBV: 66.21 (+1.86)
Biogen Idec to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Dec 22, 3:01PM CST
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the 33rd Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 12, 2015 at 3:30 p.m. PT, 6:30 p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
BIIB: 340.89 (+5.13), JPM: 62.48 (unch)
Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 2:20PM CST
Celgene Corporation announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion for continuous oral treatment with Revlimid.
BIIB: 340.89 (+5.13), JNJ: 104.59 (+0.31), AMGN: 160.67 (+3.15), CELG: 109.60 (+3.48)
Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 2:10PM CST
Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended Tresiba for expanded use.
AGN: 210.12 (+0.95), BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), ABBV: 66.21 (+1.86)
Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 1:50PM CST
Eli Lilly and Company (LLY) and Adocia entered into a licensing agreement to develop an ultra-rapid insulin, BioChaperone Lispro, for type I and type II diabetes.
BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), LLY: 70.16 (+0.42), MNKD: 5.68 (+0.18)
Roche Loses A Little Luster Before Year-End
Stephen Simpson, CFA - at Seeking Alpha - Mon Dec 22, 1:45PM CST
BIIB: 340.89 (+5.13), IMGN: 5.90 (+0.13)